Optimal Macronutrient Intake Trial to Prevent Heart Disease (OMNI Heart) - Catalog

  • Name

    Optimal Macronutrient Intake Trial to Prevent Heart Disease (OMNI Heart)

  • Accession Number

    HLB00831119a

  • Acronym

    OMNI Heart

  • Related studies
  • BSI Study IDs

    OHS

  • Is public use dataset

    False

  • Keywords
  • Ingestion Status
    Released
  • Has Study Datasets

    True

  • Has Specimens

    True

  • Specimen ID Type
    Coded
  • Study Website
  • The Framingham Heart Study Group requires that the requestor must obtain full or expedited IRB/Ethics Committee review and approval to obtain these data. Waivers or a determination that the research is exempt from ethical regulations do not suffice.

    False

  • Clinical Trial URLs
  • Study type
    Clinical Trial
  • Collection Type
    Open BioLINCC Study
  • Cohort type
    Adult
  • Interventions

    Behavioral: Diet therapy

  • Study Open Date (Data)

    2011-07-06

  • Study Open Date (Specimens)

    2011-07-06

  • Date materials available

    2010-03-04

  • Last updated

    None

  • Study period

    2002 - 2008

  • Study Contacts
  • NHLBI Division

    DCVS

  • Classification
    Heart
  • HIV study classification
    non-HIV
  • COVID study classification
    non-COVID
  • Pre-Website # of Specimens Shipped

    2075

  • # of Returned Specimens

    0

  • Primary Publication URLs
  • Conditions
    Atherosclerosis
    Cardiovascular Diseases
    Heart Diseases
    Hypertension
  • Objectives

    The objective of this study was to compare the effects of 3 healthy diets, each with reduced saturated fat intake, on blood pressure and serum lipids.

  • Background

    While reduced intake of saturated fat is widely recommended for the prevention of cardiovascular disease (CVD), the type of macronutrient (carbohydrate, protein, or unsaturated fat) that should replace saturated fat was unresolved.

  • Participants

    The trial included 164 total subjects recruited from 2 clinical centers: Johns Hopkins Medical Institutions (Baltimore, MD) and Brigham and Women’s Hospital (Boston, MA). Subjects were generally healthy adults, age ≥30 years with a systolic blood pressure (SBP) 120-159 mm Hg or diastolic blood pressure (DBP) 80-99 mm Hg. This range includes individuals with prehypertension (systolic, 120-139 mm Hg or diastolic, 80-89 mm Hg) and stage 1 hypertension (systolic, 140-159 mm Hg or diastolic, 90-99 mm Hg). Exclusion criteria included diabetes, prior or active CVD, LDL-cholesterol >220 mg/dL, fasting triglycerides >750 mg/dL, weight more than 350lb, taking medication for reduction of blood pressure lipid levels, unwillingness to stop taking vitamin and mineral supplements, and alcoholic intake of more than 14 drinks per week. The mean age of the participants was 53.6 years, 45% were women, and 55% were African American.

  • Design

    Three healthy diets were tested: a carbohydrate-rich diet similar to the DASH diet, a protein rich diet−about half from plants, and a diet rich in unsaturated fat, mostly monosaturated fat. Subjects spent 3 periods of 6 weeks on each diet. There was 2-4 week washout periods in between the diets−subjects ate their own food during these periods. At the beginning of the study there was a run-in period of 6 days, afterwards the subjects were randomized to 1 of the 6 sequences of the 3 diets. All the food during the study was provided by the researchers. The participants came to the study site weekdays for lunch and food for the other two daily meals, snacks, and weekend meals were provided for the participants to take home. Calories were adjusted in order to maintain weight and to avoid confounding effects of weight loss in the study. Potassium and sodium were also maintained during the study.

  • Conclusions

    A healthy diet with partial substitution of carbohydrate with either protein or monosaturated fat can further lower blood pressure, improve lipid levels, and reduce estimated cardiovascular risk.

  • Disease classification
  • Publications

    Appel LJ, Sacks FM, Carey VJ, Obarzanek E, Swain JF, Miller ER 3rd, Conlin PR, Erlinger TP, Rosner BA, Laranjo NM, Charleston J, McCarron P, Bishop LM; OmniHeart Collaborative Research Group. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA. 2005 Nov 16;294(19):2455-64.


    Furtado JD, Campos H, Sumner AE, Appel LJ, Carey VJ, Sacks FM. Dietary interventions that lower lipoproteins containing apolipoprotein C-III are more effective in whites than in blacks: results of the OmniHeart trial. Am J Clin Nutr. 2010 Oct;92(4):714-22. Epub 2010 Sep 8.

  • Mat types
    Plasma
    Serum
    Urine
  • Network

The study population available in BioLINCC study data may be lower than total study enrollment due to Informed Consent restrictions and other factors.

  • Subjects

    164


    Last Modified: July 28, 2014, 1:44 p.m.
  • Age
     FrequencyPercent
    26-3031.83
    31-3595.49
    36-4095.49
    41-45137.93
    46-503420.73
    51-552817.07
    56-602917.68
    61-651710.37
    66-70169.76
    71-7521.22
    76-8042.44

    Last Modified: Nov. 7, 2024, 2:56 p.m.
  • Sex
     FrequencyPercent
    Male9155.49
    Female7344.51

    Last Modified: Nov. 7, 2024, 2:56 p.m.
  • Race
     FrequencyPercent
    African American9054.88
    Non-African American7445.12

    Last Modified: Nov. 7, 2024, 2:56 p.m.

Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3.0 of the BioLINCC Handbook describes the components of the review process.

  • Material Types

    Last Modified: Nov. 30, 2015, 2:06 p.m.
  • General Freeze/Thaw Status
  • Visits (Vials)

    11/07/2024

     

    Serum

    Plasma

    Urine

    Total

    Screening Visit 3

    814

    568

    1,006

    2,388

    Intervention Period 1 Week 4

    964

    1,105

    0

    2,069

    Intervention Period 1 Week 6

    654

    542

    1,005

    2,201

    Intervention Period 2 Week 4

    969

    1,103

    0

    2,072

    Intervention Period 2 Week 6

    647

    539

    982

    2,168

    Intervention Period 3 Week 4

    921

    1,060

    0

    1,981

    Intervention Period 3 Week 6

    626

    521

    952

    2,099

     

     


    Last Modified: Nov. 7, 2024, 3:02 p.m.
  • Visits (Subjects)

    11/07/2024

     

    Serum

    Total number of subjects

    Average volume (ml) per subject

    Screening Visit 3

    161

    6.13

    Intervention Period 1 Week 4

    162

    7.71

    Intervention Period 1 Week 6

    162

    5.39

    Intervention Period 2 Week 4

    162

    7.94

    Intervention Period 2 Week 6

    162

    5.36

    Intervention Period 3 Week 4

    158

    7.70

    Intervention Period 3 Week 6

    158

    5.20

     

     

    Plasma

    Total number of subjects

    Average volume (ml) per subject

    Screening Visit 3

    161

    1.88

    Intervention Period 1 Week 4

    162

    6.46

    Intervention Period 1 Week 6

    159

    1.87

    Intervention Period 2 Week 4

    162

    6.38

    Intervention Period 2 Week 6

    160

    1.86

    Intervention Period 3 Week 4

    157

    6.23

    Intervention Period 3 Week 6

    157

    1.79

     

     

    Urine

    Total number of subjects

    Average volume (ml) per subject

    Screening Visit 3

    143

    5.91

    Intervention Period 1 Week 6

    154

    5.70

    Intervention Period 2 Week 6

    157

    5.80

    Intervention Period 3 Week 6

    150

    5.87


    Last Modified: Nov. 7, 2024, 3:02 p.m.